Endocrine side effects of cancer immunotherapy

Endocrine-Related Cancer

Volumn 24, Issue 12, 2017, Pages T331-T347

  Cukier, Priscilla ^a   Santini, Fernando C ^a   Scaranti, Mariana ^a   Hoff, Ana O ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Cancer immunotherapy; Endocrine side effects; Hypophysitis; Immune checkpoint inhibitors; Thyroid

Indexed keywords

ANTINEOPLASTIC AGENT; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4 ANTIBODY; HYDROCORTISONE; IPILIMUMAB; LEVOTHYROXINE; NIVOLUMAB;

ADRENAL INSUFFICIENCY; CANCER DIAGNOSIS; CANCER IMMUNOTHERAPY; CANCER INCIDENCE; ENDOCRINE DISEASE; HUMAN; HYPOPARATHYROIDISM; HYPOPHYSITIS; IMMUNOBIOLOGY; INSULIN DEPENDENT DIABETES MELLITUS; REVIEW; THYROID DISEASE; COMPLICATION; IMMUNOTHERAPY; PROCEDURES;

ENDOCRINE SYSTEM DISEASES; HUMANS; IMMUNOTHERAPY;

EID: 85041076967     PISSN: 13510088     EISSN: 14796821     Source Type: Journal    
DOI: 10.1530/ERC-17-0358     Document Type: Review

References (163)

1. Abdel-Rahman O, ElHalawani H & Fouad M 2016 Risk of endocrine complications in cancer patients treated with immune check point inhibitors: a meta-analysis. Future Oncology 12 413–425. (doi:10.2217/fon.15.222)
2. Aglietta M, Barone C, Sawyer MB, Moore MJ, Miller WH Jr, Bagalà C, Colombi F, Cagnazzo C, Gioeni L, Wang E, et al. 2014 A phase I dose escalation trial of tremelimumab (CP-675,206) in combination with gemcitabine in chemotherapy-naive patients with metastatic pancreatic cancer. Annals of Oncology 25 1750–1755. (doi:10.1093/ annonc/mdu205)
3. Albarel F, Gaudy C, Castinetti F, Carré T, Morange I, Conte-Devolx B, Grob JJ & Brue T 2015 Long-term follow-up of ipilimumab-induced hypophysitis, a common adverse event of the anti-CTLA-4 antibody in melanoma. European Journal of Endocrinology 172 195–204. (doi:10.1530/EJE-14-0845)
4. Altomonte M, Di Giacomo A, Queirolo P, Ascierto P, Spagnolo F, Bajetta E, Calabrò L, Danielli R, de Rosa F, Maur M, et al. 2013 Clinical experience with ipilimumab 10mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. Journal of Experimental and Clinical Cancer Research 32 82. (doi:10.1186/1756-9966-32-82)
5. Ansell SM, Hurvitz SA, Koenig PA, LaPlant BR, Kabat BF, Fernando D, Habermann TM, Inwards DJ, Verma M, Yamada R, et al. 2009 Phase I study of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with relapsed and refractory B-cell non-Hodgkin lymphoma. Clinical Cancer Research 15 6446–6453. (doi:10.1158/1078-0432.CCR-09-1339)
6. Ansell SM, Lesokhin AM, Borrello I, Halwani A, Scott EC, Gutierrez M, Schuster SJ, Millenson MM, Cattry D, Freeman GJ, et al. 2015 PD-1 blockade with nivolumab in relapsed or refractory Hodgkin’s lymphoma. New England Journal of Medicine 372 311–319. (doi:10.1056/NEJMoa1411087)
7. Antonia SJ, Bendell JC, Taylor MH, Calvo E, Jaeger D, Braud FGD, Ott PA, Pietanza MC, Horn L, Le DT, et al. 2015a Phase I/II study of nivolumab with or without ipilimumab for treatment of recurrent small cell lung cancer (SCLC): CA209-032. Journal of Clinical Oncology 33 (15 Suppl) 7503. (doi:10.1200/jco.2015.33.15_suppl.7503)
8. Antonia SJ, Goldberg SB, Balmanoukian AS, Sanborn RE, Steele K, Narwal R, Robbins PB, Gu Y, Karakunnel JJ & Rizvi NA 2015b Phase Ib study of MEDI4736, a programmed cell death ligand-1 (PD-L1) antibody, in combination with tremelimumab, a cytotoxic T-lymphocyte-associated protein-4 (CTLA-4) antibody, in patients (pts) with advanced NSCLC. Journal of Clinical Oncology 33 (15 Suppl) 3014 (doi:10.1200/jco.2015.33.15_suppl.3014)
9. Antonia SJ, López-Martin JA, Bendell J, Ott PA, Taylor M, Eder JP, Jäger D, Pietanza MC, Le DT, de Braud F, et al. 2016 Nivolumab alone and nivolumab plus ipilimumab in recurrent small-cell lung cancer (CheckMate 032): a multicentre, open-label, phase 1/2 trial. Lancet Oncology 17 883–895. (doi:10.1016/S1470-2045(16)30098-5)
10. Atkins MB, Choueiri TK, Hodi FS, Thompson JA, Hwu WJ, McDermott DF, Brookes M, Tosolini A, Ebbinghaus S, Yang Z, et al. 2015 Pembrolizumab (MK-3475) plus low-dose ipilimumab (IPI) in patients (pts) with advanced melanoma (MEL) or renal cell carcinoma (RCC): data from the KEYNOTE-029 phase 1 study. Journal of Clinical Oncology 33 (15 Suppl) 3009 (doi:10.1200/ jco.2015.33.15_suppl.3009)
11. Attia P, Phan GQ, Maker AV, Robinson MR, Quezado MM, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, et al. 2005 Autoimmunity correlates with tumor regression in patients with metastatic melanoma treated with anti-cytotoxic T-lymphocyte antigen-4. Journal of Clinical Oncology 23 6043–6053. (doi:10.1200/ JCO.2005.06.205)
12. Bacanovic S, Burger IA, Stolzmann P, Hafner J & Huellner MW. 2015 Ipilimumab-induced adrenalitis: a possible pitfall in 18F-FDG-PET/ CT. Clinical Nuclear Medicine 40 518–519. (doi:10.1097/ RLU.0000000000000887)
13. Bauer TM, McCleod M, Chandler JC, Blumenschein GR, Schwartzberg LS, Burris H, Waterhouse D, Jotte RM, Hussein M, Spigel DR, et al. 2015 An ongoing phase IIIb/IV safety trial of nivolumab (NIVO) in patients (pts) with advanced or metastatic non-small-cell lung cancer (NSCLC) w.ho progressed after receiving 1 or more prior systemic regimens. Journal of Clinical Oncology 33 (15 Suppl) 3013 (doi:10.1200/jco.2015.33.15_suppl.3013)
14. Borghaei H, Paz-Ares L, Horn L, Spigel DR, Steins M, Ready NE, Chow LQ, Vokes EE, Felip E, Holgado E, et al. 2015 Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer. New England Journal of Medicine 373 1627–1639. (doi:10.1056/NEJMoa1507643)
15. Borodic G, Hinkle DM & Cia Y 2011 Drug-induced graves disease from CTLA-4 receptor suppression. Ophthalmic Plastic and Reconstructive Surgery 27 e87–e88. (doi:10.1097/IOP.0b013e3181ef72a1)
16. Bossart S, Thurneysen S, Rushing E, Frontzek K, Leske H, Mihic-Probst D, Nagel HW, Mangana J, Goldinger SM & Dummer R 2017 Case report: encephalitis, with brainstem involvement, following checkpoint inhibitor therapy in metastatic melanoma. Oncologist 22 749–753. (doi:10.1634/theoncologist.2016-0366)
17. Boussiotis VA 2016 Molecular and biochemical aspects of the PD-1 checkpoint pathway. New England Journal of Medicine 375 1767–1778. (doi:10.1056/NEJMra1514296)
18. Boutros C, Tarhini A, Routier E, Lambotte O, Ladurie FL, Carbonnel F, Izzeddine H, Marabelle A, Champiat S, Berdelou A, et al. 2016 Safety profiles of anti-CTLA-4 and anti-PD-1 antibodies alone and in combination. Nature Reviews Clinical Oncology 13 473–486. (doi:10.1038/nrclinonc.2016.58)
19. Brahmer JR, Drake CG, Wollner I, Powderly JD, Picus J, Sharfman WH, Stankevich E, Pons A, Salay TM, McMiller TL, et al. 2010 Phase I study of single-agent anti-programmed death-1 (MDX-1106) in refractory solid tumors: safety, clinical activity, pharmacodynamics, and immunologic correlates. Journal of Clinical Oncology 28 3167–3175. (doi:10.1200/JCO.2009.26.7609)
20. Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. 2012 Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. New England Journal of Medicine 366 2455–2465. (doi:10.1056/ NEJMoa1200694)
21. Brahmer J, Reckamp KL, Baas P, Crinò L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. 2015 Nivolumab versus docetaxel in advanced squamous-cell non-small-cell lung cancer. New England Journal of Medicine 373 123–135. (doi:10.1056/ NEJMoa1504627)
22. Bruhns P, Iannascoli B, England P, Mancardi DA, Fernandez N, Jorieux S & Daëron M 2009 Specificity and affinity of human Fcgamma receptors and their polymorphic variants for human IgG subclasses. Blood 113 3716–3725. (doi:10.1182/blood-2008-09-179754)
23. Byun DJ, Wolchok JD, Rosenberg LM & Girotra M 2017 Cancer immunotherapy – immune checkpoint blockade and associated endocrinopathies. Nature Reviews Endocrinology 13 195–207. (doi:10.1038/nrendo.2016.205)
24. Calabrò L, Morra A, Fonsatti E, Cutaia O, Fazio C, Annesi D, Lenoci M, Amato G, Danielli R, Altomonte M, et al. 2015 Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. Lancet Respiratory Medicine 3 301–309. (doi:10.1016/S2213-2600(15)00092-2)
25. Camacho LH, Antonia S, Sosman J, Kirkwood JM, Gajewski TF, Redman B, Pavlov D, Bulanhagui C, Bozon VA, Gomez-Navarro J, et al. 2009 Phase I/II trial of tremelimumab in patients with metastaticmelanoma. Journal of Clinical Oncology 27 1075–1081. (doi:10.1200/JCO.2008.19.2435)
26. Carl D, Grüllich C, Hering S & Schabet M 2015 Steroid responsive encephalopathy associated with autoimmune thyroiditis following ipilimumab therapy: a case report. BMC Research Notes 8 316. (doi:10.1186/s13104-015-1283-9)
27. Chen DS, Irving BA & Hodi FS 2012 Molecular pathways: next generation immunotherapy: inhibiting programmed death-ligand 1 and programmed death-1. Clinical Cancer Research 18 6580–6587. (doi:10.1158/1078-0432.CCR-12-1362)
28. Chiarion-Sileni V, Pigozzo J, Ascierto PA, Simeone E, Maio M, Calabrò L, Marchetti P, De Galitiis F, Testori A, Ferrucci PF, et al. 2014 Ipilimumab retreatment in patients with pretreated advanced melanoma: the expanded access programme in Italy. British Journal of Cancer 110 1721–1726. (doi:10.1038/bjc.2014.126)
29. Cho DC, Sosman JA, Sznol M, Gordon MS, Hollebecque A, Hamid O, McDermott DF, Delord JP, Rhee IP, Mokatrin A, et al. 2013 Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with metastatic renal cell carcinoma (mRCC). Journal of Clinical Oncology 31 (15 Suppl) 4505 (doi:10.1200/ jco.2013.31.15_suppl.4505)
30. Chung KY, Gore I, Fong L, Venook A, Beck SB, Dorazio P, Criscitiello PJ, Healey DI, Huang B, Gomez-Navarro J, et al. 2010 Phase II study of the anti-cytotoxic T-lymphocyte-associated antigen 4 monoclonal antibody, tremelimumab, in patients with refractory metastatic colorectal cancer. Journal of Clinical Oncology 28 3485–3490. (doi:10.1200/JCO.2010.28.3994)
31. Corsello SM, Barnabei A, Marchetti P, De Vecchis L, Salvatori R & Torino F 2013 Endocrine side effects induced by immune checkpoint inhibitors. Journal of Clinical Endocrinology and Metabolism 98 1361–1375. (doi:10.1210/jc.2012-4075)
32. Crews J, Agarwal A, Jack L, Xu D, Do DV & Nguyen QD 2015 Ipilimumab-associated retinopathy. Ophthalmic Surgery, Lasers and Imaging Retina 46 658–660. (doi:10.3928/23258160-20150610-10)
33. Di Giacomo AM, Danielli R, Calabrò L, Bertocci E, Nannicini C, Giannarelli D, Balestrazzi A, Vigni F, Riversi V, Miracco C, et al. 2011 Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). Cancer Immunology, Immunotherapy 60 467–477. (doi:10.1007/s00262-010-0958-2)
34. Di Giacomo AM, Ascierto PA, Pilla L, Santinami M, Ferrucci PF, Giannarelli D, Marasco A, Rivoltini L, Simeone E, Nicoletti SV, et al. 2012 Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. Lancet Oncology 13 879–886. (doi:10.1016/S1470-2045(12)70324-8)
35. Disis ML, Patel MR, Pant S, Infante JR, Lockhart AC, Kelly K, Beck JT, Gordon MS Weiss GJ, Ejadi S, et al. 2015 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with previously treated, recurrent or refractory ovarian cancer: a phase Ib, open-label expansion trial. Journal of Clinical Oncology 33 (15 Suppl) 5509 (doi:10.1200/jco.2015.33.15_suppl.5509)
36. Dillard T, Yedinak CG, Alumkal J & Fleseriu M 2010 Anti-CTLA-4 antibody therapy associated autoimmune hypophysitis: serious immune related adverse events across a spectrum of cancer subtypes. Pituitary 13 29–38. (doi:10.1007/s11102-009-0193-z)
37. Doi T, Piha-Paul SA, Jalal SI, Mai-Dang H, Yuan S, Koshiji M, Csiki I & Bennouna J 2015 Pembrolizumab (MK-3475) for patients (pts) with advanced esophageal carcinoma: Preliminary results from KEYNOTE-028. Journal of Clinical Oncology 33 (3 Suppl) 4010 (doi:10.1200/jco.2015.33.3_suppl.774)
38. Downey SG, Klapper JA, Smith FO, Yang JC, Sherry RM, Royal RE, Kammula US, Hughes MS, Allen TE, Levy CL, et al. 2007 Prognostic factors related to clinical response in patients with metastatic melanoma treated by CTL-associated antigen-4 blockade. Clinical Cancer Research 13 6681–6688. (doi:10.1158/1078-0432.CCR-07-0187)
39. Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, Hamid O, Robert C, Ascierto PA, Richards JM, et al. 2016 Prolonged survival in stage III melanoma with ipilimumab adjuvant therapy. New England Journal of Medicine 375 1845–1855. (doi:10.1056/NEJMoa1611299)
40. El-Khoueiry AB, Melero I, Crocenzi TS, Welling TH, Yau TC, Yeo W, Chopra A, Grosso J, Lang L, Anderson J, et al. 2015 Phase I/II safety and antitumor activity of nivolumab in patients with advanced hepatocellular carcinoma (HCC): CA209-040. Journal of Clinical Oncology 33 (18 Suppl) LBA101 (doi:10.1200/jco.2015.33.18_suppl. lba101)
41. El-Khoueiry AB, Sangro B, Yau T, Crocenzi TS, Kudo M, Hsu C, Kim TY, Choo SP, Trojan J, Welling TH, et al. 2017 Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389 2492–2502. (doi:10.1016/S0140-6736(17)31046-2)
42. Faje A 2016 Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights. Pituitary 19 82–92. (doi:10.1007/ s11102-015-0671-4)
43. Faje AT, Sullivan R, Lawrence D, Tritos NA, Fadden R, Klibanski A & Nachtigall L 2014 Ipilimumab-induced hypophysitis: a detailed longitudinal analysis in a large cohort of patients with metastatic melanoma. Journal of Clinical Endocrinology and Metabolism 99 4078–4085. (doi:10.1210/jc.2014-2306)
44. Ferris RL, Blumenschein G, Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. 2016 Nivolumab for recurrent squamous-cell carcinoma of the head and neck. New England Journal of Medicine 375 1856–1867. (doi:10.1056/ NEJMoa1602252)
45. Francisco LM, Sage PT & Sharpe AH 2010 The PD-1 pathway in tolerance and autoimmunity. Immunological Reviews 236 219–242. (doi:10.1111/j.1600-065X.2010.00923.x)
46. Friedman CF, Proverbs-Singh TA & Postow MA 2016 Treatment of the immune-related adverse effects of immune checkpoint inhibitors: a review. JAMA Oncology 2 1346–1353. (doi:10.1001/ jamaoncol.2016.1051)
47. Garon EB, Rizvi NA, Hui R, Leighl N, Balmanoukian AS, Eder JP, Patnaik A, Aggarwal C, Gubens M, Horn L, et al. 2015 Pembrolizumab for the treatment of non-small-cell lung cancer. New England Journal of Medicine 372 2018–2028. (doi:10.1056/ NEJMoa1501824)
48. Garred P, Michaelsen TE & Aase A 1989 The IgG subclass pattern of complement activation depends on epitope density and antibody and complement concentration. Scandinavian Journal of Immunology 30 379–382. (doi:10.1111/j.1365-3083.1989.tb01225.x)
49. Gettinger SN, Hellmann MD, Shepherd FA, Antonia SJ, Brahmer JR, Chow LQM, Goldman JW, Juergens RA, Borghaei H, Ready N, et al. 2015 First-line monotherapy with nivolumab (NIVO; anti-programmed death-1 [PD-1]) in advanced non-small cell lung cancer (NSCLC): safety, efficacy and correlation of outcomes with PD-1 ligand (PD-L1) expression. Journal of Clinical Oncology 33 (15 Suppl) 8025. (doi:10.1200/jco.2015.33.15_suppl.8025)
50. González-Rodríguez E, Rodríguez-Abreu D & Spanish Group for Cancer Immuno-Biotherapy (GETICA) 2016 Immune checkpoint inhibitors: review and management of endocrine adverse events. Oncologist 21 804–816. (doi:10.1634/theoncologist.2015-0509)
51. Gulley JL, Spigel D, Kelly K, Chandler JC, Rajan A, Hassan R, Wong DJL, Leach J, Edenfield WJ, Wang D, et al. 2015 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in advanced NSCLC patients: a phase 1b, open-label expansion trial in patients progressing after platinum-based chemotherapy. Journal of Clinical Oncology 33 (15 Suppl) 8034. (doi:10.1200/jco.2015.33.15_ suppl.8034)
52. Hamanishi J, Mandai M, Ikeda T, Minami M, Kawaguchi A, Murayama T, Kanai M, Mori Y, Matsumoto S, Chikuma S, et al. 2015 Safety and antitumor activity of anti-PD-1 antibody, nivolumab, in patients with platinum-resistant ovarian cancer. Journal of Clinical Oncology 33 4015–4022. (doi:10.1200/JCO.2015.62.3397)
53. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, Wolchok JD, Hersey P, Joseph RW, Weber JS, et al. 2013 Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. New England Journal of Medicine 369 134–144. (doi:10.1056/ NEJMoa1305133)
54. Hammers HJ, Plimack ER, Sternberg C, McDermott DF, Larkin JMG, Ravaud A, Rini BI, Sharma P, Bhagavatheeswaran P, Gagnier P, et al. 2015 CheckMate 214: a phase III, randomized, open-label study of nivolumab combined with ipilimumab versus sunitinib monotherapy in patients with previously untreated metastatic renal cell carcinoma. Journal of Clinical Oncology 33 (15 Suppl) TPS4578 (doi:10.1200/jco.2015.33.15_suppl.tps4578)
55. Hamnvik OP, Larsen PR & Marqusee E 2011 Thyroid dysfunction from antineoplastic agents. Journal of the National Cancer Institute 103 1572–1587. (doi:10.1093/jnci/djr373)
56. Hellmann MD, Rizvi NA, Goldman JW, Gettinger SN, Borghaei H, Brahmer JR, Ready NE, Gerber DE, Chow LQ, Juergens RA, et al. 2017 Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncology 18 31–41. (doi:10.1016/S1470-2045(16)30624-6)
57. Henderson AD & Thomas DA 2015 A case report of orbital inflammatory syndrome secondary to ipilimumab. Ophthalmic Plastic and Reconstructive Surgery 31 68–70. (doi:10.1097/IOP.0000000000000081)
58. Herbst RS, Gordon MS, Fine GD, Sosman JA, Soria JC, Hamid O, Powderly JD, Burris HA, Mokatrin A, Kowanetz M, et al. 2013 A study of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic tumors. Journal of Clinical Oncology 31 (15 Suppl) 3000. (doi:10.1200/jco.2013.31.15_ suppl.3000)
59. Hersh EM, O’Day SJ, Powderly J, Khan KD, Pavlick AC, Cranmer LD, Samlowski WE, Nichol GM, Yellin MJ & Weber JS 2011 A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advancedmelanoma. Investigational New Drugs 29 489–498. (doi:10.1007/s10637-009-9376-8)
60. Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, Gonzalez R, Robert C, Schadendorf D, Hassel JC, et al. 2010 Improved survival with ipilimumab in patients with metastatic melanoma. New England Journal of Medicine 363 711–723. (doi:10.1056/NEJMoa1003466)
61. Hodi FS, Lee S, McDermott DF, Rao UN, Butterfield LH, Tarhini AA, Leming P, Puzanov I, Shin D & Kirkwood JM 2014 Ipilimumab plus sargramostim vs ipilimumab alone for treatment of metastatic melanoma: a randomized clinical trial. JAMA 312 1744–1753. (doi:10.1001/jama.2014.13943)
62. Hodi FS, Postow MA, Chesney JA, Pavlick AC, Robert C, Grossmann KF, McDermott DF, Linette GP, Meyer N, Giguere JK, et al. 2015 Clinical response, progression-free survival (PFS), and safety in patients (pts) with advanced melanoma (MEL) receiving nivolumab (NIVO) combined with ipilimumab (IPI) vs IPI monotherapy in CheckMate 069 study. Journal of Clinical Oncology 33 (15 Suppl) 9004. (doi:10.1200/jco.2015.33.15_suppl.9004)
63. Horvat TZ, Adel NG, Dang TO, Momtaz P, Postow MA, Callahan MK, Carvajal RD, Dickson MA, D’Angelo SP, Woo KM, et al. 2015 Immune-related adverse events, need for systemic immunosuppression, and effects on survival and time to treatment failure in patients with melanoma treated with ipilimumab at memorial sloan kettering cancer center. Journal of Clinical Oncology 33 3193–3198. (doi:10.1200/JCO.2015.60.8448)
64. Ibrahim RA, Berman DM, DePril V, Humphrey RW, Chen T, Messina M, Chin KM, Liu HY, Bielefield M & Hoos A 2011 Ipilimumab safety profile: summary of findings from completed trials in advanced melanoma. Journal of Clinical Oncology 29 (15 Suppl) 8583. (doi:10.1200/jco.2011.29.15_suppl.8583)
65. Iguchi H, Nogami N, Kozuki T, Matsumoto T, Tamura K, Yamamoto N, Shimomura A, Hoshino Y, Michibata Y, Nii M, et al. 2015 Phase I study to evaluate the safety and tolerability of MEDI4736, an anti-programmed cell death ligand-1 (PD-L1) antibody, in Japanese patients with advanced solid tumors. Journal of Clinical Oncology 33 (15 Suppl) 3039. (doi:10.1200/jco.2015.33.15_suppl.3039)
66. Iwama S, De Remigis A, Callahan MK, Slovin SF, Wolchok JD & Caturegli P 2014 Pituitary expression of CTLA-4 mediates hypophysitis secondary to administration of CTLA-4 blocking antibody. Science Translational Medicine 6 230ra245. (doi:10.1126/ scitranslmed.3008002)
67. Joshi MN, Whitelaw BC, Palomar MT, Wu Y & Carroll PV 2016 Immune checkpoint inhibitor-related hypophysitis and endocrine dysfunction: clinical review. Clinical Endocrinology 85 331–339. (doi:10.1111/cen.13063)
68. Kazlauskaite R, Evans AT, Villabona CV, Abdu TA, Ambrosi B, Atkinson AB, Choi CH, Clayton RN, Courtney CH, Gonc EN, et al. 2008 Corticotropin tests for hypothalamic-pituitary-adrenal insufficiency: a metaanalysis. Journal of Clinical Endocrinology and Metabolism 93 4245–4253. (doi:10.1210/jc.2008-0710)
69. Kelly K, Patel MR, Infante JR, Iannotti N, Nikolinakos P, Leach J, Wang D, Chandler JC, Jerusalem GHM, Gurtler JS, et al. 2015 Avelumab (MSB0010718C), an anti-PD-L1 antibody, in patients with metastatic or locally advanced solid tumors: assessment of safety and tolerability in a phase I, open-label expansion study. Journal of Clinical Oncology 33 (15 Suppl) 3044. (doi:10.1200/jco.2015.33.15_ suppl.3044)
70. Kindler HL, Scherpereel A, Calabrò L, Aerts J, Perez SC, Bearz A, Nackaerts K, Fennell DA, Kowalski D, Tsao AS, et al. 2016 Tremelimumab as second- or third-line treatment of unresectable malignant mesothelioma (MM): results from the global, double-blind, placebo-controlled determine study. Journal of Clinical Oncology 34 (15 Suppl) 8502. (doi:10.1200/JCO.2016.34.15_ suppl.8502)
71. Kirkwood JM, Lorigan P, Hersey P, Hauschild A, Robert C, McDermott D, Marshall MA, Gomez-Navarro J, Liang JQ & Bulanhagui CA 2010 Phase II trial of tremelimumab (CP-675,206) in patients with advanced refractory or relapsed melanoma. Clinical Cancer Research 16 1042–1048. (doi:10.1158/1078-0432.CCR-09-2033)
72. Kitabchi AE, Umpierrez GE, Miles JM & Fisher JN 2009 Hyperglycemic crises in adult patients with diabetes. Diabetes Care 32 1335–1343. (doi:10.2337/dc09-9032)
73. Klocke K, Sakaguchi S, Holmdahl R & Wing K 2016 Induction of autoimmune disease by deletion of CTLA-4 in mice in adulthood. PNAS 113 E2383–E2392. (doi:10.1073/pnas.1603892113)
74. Ku GY, Yuan J, Page DB, Schroeder SE, Panageas KS, Carvajal RD, Chapman PB, Schwartz GK, Allison JP & Wolchok JD 2010 Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting: lymphocyte count after 2 doses correlates with survival. Cancer 116 1767–1775. (doi:10.1002/ cncr.24951)
75. Kuehn HS, Ouyang W, Lo B, Deenick EK, Niemela JE, Avery DT, Schickel JN, Tran DQ, Stoddard J, Zhang Y, et al. 2014 Immune dysregulation in human subjects with heterozygous germline mutations in CTLA4. Science 345 1623–1627. (doi:10.1126/ science.1255904)
76. Kumar V, Chaudhary N, Garg M, Floudas CS, Soni P & Chandra AB 2017 Current diagnosis and management of immune related adverse events (irAEs) induced by immune checkpoint inhibitor therapy. Frontiers in Pharmacology 8 49. (doi:10.3389/fphar.2017.00049)
77. Kwon ED, Drake CG, Scher HI, Fizazi K, Bossi A, van den Eertwegh AJ, Krainer M, Houede N, Santos R, Mahammedi H, et al. 2014 Ipilimumab versus placebo after radiotherapy in patientswith metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. Lancet Oncology 15 700–712. (doi:10.1016/S1470-2045(14)70189-5)
78. Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. 2015 Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. New England Journal of Medicine 373 23–34. (doi:10.1056/ NEJMoa1504030)
79. Latchman Y, Wood CR, Chernova T, Chaudhary D, Borde M, Chernova I, Iwai Y, Long AJ, Brown JA, Nunes R, et al. 2001 PD-L2 is a second ligand for PD-1 and inhibits T cell activation. Nature Immunology 2 261–268. (doi:10.1038/85330)
80. Laurent S, Queirolo P, Boero S, Salvi S, Piccioli P, Boccardo S, Minghelli S, Morabito A, Fontana V, Pietra G, et al. 2013 The engagement of CTLA-4 on primary melanoma cell lines induces antibody-dependent cellular cytotoxicity and TNF-α production. Journal of Translational Medicine 11 108. (doi:10.1186/1479-5876-11-108)
81. Le DT, Uram JN, Wang H, Bartlett BR, Kemberling H, Eyring AD, Skora AD, Luber BS, Azad NS, Laheru D, et al. 2015 PD-1 blockade in tumors with mismatch-repair deficiency. New England Journal of Medicine 372 2509–2520. (doi:10.1056/NEJMoa1500596)
82. Lo JA, Fisher DE & Flaherty KT 2015 Prognostic significance of cutaneous adverse events associated with pembrolizumab therapy. JAMA Oncology 1 1340–1341. (doi:10.1001/jamaoncol.2015.2274)
83. Lu J, Lee-Gabel L, Nadeau MC, Ferencz TM & Soefje SA 2015 Clinical evaluation of compounds targeting PD-1/PD-L1 pathway for cancer immunotherapy. Journal of Oncology Pharmacy Practice 21 451–467. (doi:10.1177/1078155214538087)
84. Lutzky J, Antonia SJ, Blake-Haskins A, Li X, Robbins PB, Shalabi AM, Vasselli J, Ibrahim RA, Khleif S & Segal NH 2014 A phase 1 study of MEDI4736, an anti-PD-L1 antibody, in patients with advanced solid tumors. Journal of Clinical Oncology 32 (15 Suppl) 3001 (doi:10.1200/ jco.2014.32.15_suppl.3001)
85. Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Neal J, Lu H, Cuillerot JM, et al. 2012 Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. Journal of Clinical Oncology 30 2046–2054. (doi:10.1200/JCO.2011.38.4032)
86. Maker AV, Yang JC, Sherry RM, Topalian SL, Kammula US, Royal RE, Hughes M, Yellin MJ, Haworth LR, Levy C, et al. 2006 Intrapatient dose escalation of anti-CTLA-4 antibody in patients with metastatic melanoma. Journal of Immunotherapy 29 455–463. (doi:10.1097/01. cji.0000208259.73167.58)
87. Margolin K, Ernstoff MS, Hamid O, Lawrence D, McDermott D, Puzanov I, Wolchok JD, Clark JI, Sznol M, Logan TF, et al. 2012 Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial. Lancet Oncology 13 459–465. (doi:10.1016/ S1470-2045(12)70090-6)
88. McElnea E, Ní Mhéalóid A, Moran S, Kelly R & Fulcher T 2014 Thyroid-like ophthalmopathy in a euthyroid patient receiving Ipilimumab. Orbit 33 424–427. (doi:10.3109/01676830.2014.949792)
89. Michaelsen TE, Garred P & Aase A 1991 Human IgG subclass pattern of inducing complement-mediated cytolysis depends on antigen concentration and to a lesser extent on epitope patchiness, antibody affinity and complement concentration. European Journal of Immunology 21 11–16. (doi:10.1002/eji.1830210103)
90. Michot JM, Bigenwald C, Champiat S, Collins M, Carbonnel F, Postel-Vinay S, Berdelou A, Varga A, Bahleda R, Hollebecque A, et al. 2016 Immune-related adverse events with immune checkpoint blockade: a comprehensive review. European Journal of Cancer 54 139–148. (doi:10.1016/j.ejca.2015.11.016)
91. Min L & Hodi FS 2014 Anti-PD1 following ipilimumab for mucosal melanoma: durable tumor response associated with severe hypothyroidism and rhabdomyolysis. Cancer Immunology Research 2 15–18. (doi:10.1158/2326-6066.CIR-13-0146)
92. Min L, Vaidya A & Becker C 2011 Thyroid autoimmunity and ophthalmopathy related to melanoma biological therapy. European Journal of Endocrinology 164 303–307. (doi:10.1530/EJE-10-0833)
93. Min L, Hodi FS, Giobbie-Hurder A, Ott PA, Luke JJ, Donahue H, Davis M, Carroll RS & Kaiser UB 2015 Systemic high-dose corticosteroid treatment does not improve the outcome of ipilimumab-related hypophysitis: a retrospective cohort study. Clinical Cancer Research 21 749–755. (doi:10.1158/1078-0432.CCR-14-2353)
94. Mitchell AL, Cordell HJ, Soemedi R, Owen K, Skinningsrud B, Wolff AB, Undlien D, Husebye E & Pearce SH 2009 Programmed death ligand 1 (PD-L1) gene variants contribute to autoimmune Addison’s disease and Graves’ disease susceptibility. Journal of Clinical Endocrinology and Metabolism 94 5139–5145. (doi:10.1210/jc.2009-1404)
95. Motzer RJ, Rini BI, McDermott DF, Redman BG, Kuzel TM, Harrison MR, Vaishampayan UN, Drabkin HA, George S, Logan TF, et al. 2015 Nivolumab for metastatic renal cell carcinoma: results of a randomized phase II trial. Journal of Clinical Oncology 33 1430–1437. (doi:10.1200/JCO.2014.59.0703)
96. Nanda R, Chow LQ, Dees EC, Berger R, Gupta S, Geva R, Pusztai L, Pathiraja K, Aktan G, Cheng JD, et al. 2016 Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 Study. Journal of Clinical Oncology 34 2460–2467. (doi:10.1200/JCO.2015.64.8931)
97. Nishio M, Hida T, Nakagawa K, Sakai H, Nogami N, Atagi S, Takahashi T, Nokihara H, Saka H, Takenoyama M, et al. 2015 Phase II studies of nivolumab (anti-PD-1, BMS-936558, ONO-4538) in patients with advanced squamous (sq) or nonsquamous (non-sq) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 33 (15 Suppl) 8027. (doi:10.1200/jco.2015.33.15_suppl.8027)
98. O’Day SJ, Maio M, Chiarion-Sileni V, Gajewski TF, Pehamberger H, Bondarenko IN, Queirolo P, Lundgren L, Mikhailov S, Roman L, et al. 2010 Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phaseII study. Annals of Oncology 21 1712–1717. (doi:10.1093/ annonc/mdq013)
99. O’Donnell PH, Plimack ER, Bellmunt J, Berger R, Montgomery RB, Heath K, Dolled-Filhart M, Pathiraja K, Gause CK, Cheng JD, et al. 2015 Journal of Clinical Oncology 33 (7 Suppl) 296. (doi:10.1200/ jco.2015.33.7_suppl.296)
100. Ott PA, Fernandez MEE, Hiret S, Kim DW, Moss RA, Winser T, Yuan S, Cheng JD, Piperdi B & Mehnert JM 2015 Pembrolizumab (MK-3475) in patients (pts) with extensive-stage small cell lung cancer (SCLC): preliminary safety and efficacy results from KEYNOTE-028. Journal of Clinical Oncology 33 (15 Suppl) 7502. (doi:10.1200/jco.2015.33.15_ suppl.7502)
101. Orlov S, Salari F, Kashat L & Walfish PG 2015 Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies. Journal of Clinical Endocrinology and Metabolism 100 1738–1741. (doi:10.1210/jc.2014-4560)
102. Ospina NS, Al Nofal A, Bancos I, Javed A, Benkhadra K, Kapoor E, Lteif AN, Natt N & Murad MH 2016 ACTH stimulation tests for the diagnosis of adrenal insufficiency: systematic review and metaanalysis. Journal of Clinical Endocrinology and Metabolism 101 427–434. (doi:10.1210/jc.2015-1700)
103. Patnaik A, Socinski MA, Gubens MA, Gandhi L, Stevenson J, Bachman RD, Bourque J, Ge JY, Im E & Gadgeel SM 2015 Phase 1 study of pembrolizumab (pembro; MK-3475) plus ipilimumab (IPI) as second-line therapy for advanced non-small cell lung cancer (NSCLC): KEYNOTE-021 cohort D. Journal of Clinical Oncology 33 (15 Suppl) 8011. (doi:10.1200/jco.2015.33.15_suppl.8011)
104. Paz-Ares L, Horn L, Borghaei H, Spigel DR, Steins M, Ready N, Chow LQM, Vokes EE, Felip E, Holgado E, et al. 2015 Phase III, randomized trial (CheckMate 057) of nivolumab (NIVO) versus docetaxel (DOC) in advanced non-squamous cell (non-SQ) non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 33 (18 Suppl) LBA109. (doi:10.1200/jco.2015.33.18_suppl.lba109)
105. Petrylak DP, Powles T, Bellmunt J, Braiteh FS, Loriot Y, Zambrano CC, Burris HA, Kim JW, Teng SM, Bruey JM, et al. 2015 A phase Ia study of MPDL3280A (anti-PDL1): updated response and survival data in urothelial bladder cancer (UBC). Journal of Clinical Oncology 33 (15 Suppl) 4501.
106. Phan GQ, Yang JC, Sherry RM, Hwu P, Topalian SL, Schwartzentruber DJ, Restifo NP, Haworth LR, Seipp CA, Freezer LJ, et al. 2003 Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. PNAS 100 8372–8377. (doi:10.1073/pnas.1533209100)
107. Pillai R, Behera M, Owonikoko T, Kamphorst A, Pakkala S, Belani C, Khuri F, Ahmed R & Ramalingam S 2016 OA03.06 evaluation of toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer (NSCLC). Journal of Thoracic Oncology 12 S253–S254. (doi:10.1016/j.jtho.2016.11.242)
108. Postow MA, Callahan MK, Barker CA, Yamada Y, Yuan J, Kitano S, Mu Z, Rasalan T, Adamow M, Ritter E, et al. 2012 Immunologic correlates of the abscopal effect in a patient with melanoma. New England Journal of Medicine 366 925–931. (doi:10.1056/NEJMoa1112824)
109. Postow MA, Chesney J, Pavlick AC, Robert C, Grossmann K, McDermott D, Linette GP, Meyer N, Giguere JK, Agarwala SS, et al. 2015 Nivolumab and ipilimumab versus ipilimumab in untreated melanoma. New England Journal of Medicine 372 2006–2017. (doi:10.1056/NEJMoa1414428)
110. Powles T, Eder JP, Fine GD, Braiteh FS, Loriot Y, Cruz C, Bellmunt J, Burris HA, Petrylak DP, Teng SL, et al. 2014 MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515 558–562. (doi:10.1038/nature13904)
111. Ralph C, Elkord E, Burt DJ, O’Dwyer JF, Austin EB, Stern PL, Hawkins RE & Thistlethwaite FC 2010 Modulation of lymphocyte regulation for cancer therapy: a phaseII trial of tremelimumab in advanced gastric and esophageal adenocarcinoma. Clinical Cancer Research 16 1662–1672. (doi:10.1158/1078-0432.CCR-09-2870)
112. Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, Sebastian M, Lu H, Cuillerot JM & Lynch TJ 2013 Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Annals of Oncology 24 75–83. (doi:10.1093/annonc/mds213)
113. Reck M, Rodríguez-Abreu D, Robinson AG, Hui R, Csőszi T, Fülöp A, Gottfried M, Peled N, Tafreshi A, Cuffe S, et al. 2016 Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. New England Journal of Medicine 375 1823–1833. (doi:10.1056/ NEJMoa1606774)
114. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, et al. 2005 Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. Journal of Clinical Oncology 23 8968–8977. (doi:10.1200/JCO.2005.01.109)
115. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, et al. 2012 Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. Journal of Translational Medicine 10 236. (doi:10.1186/1479-5876-10-236)
116. Ribas A, Kefford R, Marshall MA, Punt CJ, Haanen JB, Marmol M, Garbe C, Gogas H, Schachter J, Linette G, et al. 2013 Phase III randomized clinical trial comparing tremelimumab with standard-of-care chemotherapy in patients with advanced melanoma. Journal of Clinical Oncology 31 616–622. (doi:10.1200/JCO.2012.44.6112)
117. Ribas A, Puzanov I, Dummer R, Schadendorf D, Hamid O, Robert C, Hodi FS, Schachter J, Pavlick AC, Lewis KD, et al. 2015 Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trial. Lancet Oncology 16 908–918. (doi:10.1016/ S1470-2045(15)00083-2)
118. Ribas A, Hamid O, Daud A, Hodi FS, Wolchok JD, Kefford R, Joshua AM, Patnaik A, Hwu WJ, Weber JS, et al. 2016 Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 315 1600–1609. (doi:10.1001/ jama.2016.4059)
119. Rizvi NA, Brahmer JR, Ou S-HI, Segal NH, Khleif S, Hwu W-J, Gutierrez M, Schoffski P, Hamid O, Weiss J, et al. 2015a Safety and clinical activity of MEDI4736, an anti-programmed cell death-ligand 1 (PD-L1) antibody, in patients with non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 33 (15 Suppl) 8032. (doi:10.1200/jco.2015.33.15_suppl.8032)
120. Rizvi NA, Mazières J, Planchard D, Stinchcombe TE, Dy GK, Antonia SJ, Horn L, Lena H, Minenza E, Mennecier B, et al. 2015b Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial. Lancet Oncology 16 257–265. (doi:10.1016/S1470-2045(15)70054-9)
121. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, Weber JS, Joshua AM, Hwu WJ, Gangadhar TC, et al. 2014 Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 384 1109–1117. (doi:10.1016/S0140-6736(14)60958-2)
122. Robert C, Long GV, Brady B, Dutriaux C, Maio M, Mortier L, Hassel JC, Rutkowski P, McNeil C, Kalinka-Warzocha E, et al. 2015a Nivolumab in previously untreated melanoma without BRAF mutation. New England Journal of Medicine 372 320–330. (doi:10.1056/ NEJMoa1412082)
123. Robert C, Schachter J, Long GV, Arance A, Grob JJ, Mortier L, Daud A, Carlino MS, McNeil C, Lotem M, et al. 2015b Pembrolizumab versus ipilimumab in advanced melanoma. New England Journal of Medicine 372 2521–2532. (doi:10.1056/NEJMoa1503093)
124. Romano E, Kusio-Kobialka M, Foukas PG, Baumgaertner P, Meyer C, Ballabeni P, Michielin O, Weide B, Romero P & Speiser DE 2015 Ipilimumab-dependent cell-mediated cytotoxicity of regulatory T cells ex vivo by nonclassical monocytes in melanoma patients. PNAS A112 6140–6145. (doi:10.1073/pnas.1417320112)
125. Rosenberg JE, Hoffman-Censits J, Powles T, van der Heijden MS, Balar AV, Necchi A, Dawson N, O’Donnell PH, Balmanoukian A, Loriot Y, et al. 2016 Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial. Lancet 387 1909–1920. (doi:10.1016/ S0140-6736(16)00561-4)
126. Royal RE, Levy C, Turner K, Mathur A, Hughes M, Kammula US, Sherry RM, Topalian SL, Yang JC, Lowy I, et al. 2010 Phase 2 trial of single agent Ipilimumab (anti-CTLA-4) for locallyadvanced or metastatic pancreatic adenocarcinoma. Journal of Immunotherapy 33 828–833. (doi:10.1097/CJI.0b013e3181eec14c)
127. Rozali EN, Hato SV, Robinson BW, Lake RA & Lesterhuis WJ 2012 Programmed death ligand 2 in cancer-induced immune suppression. Clinical and Developmental Immunology 2012 8. (doi:10.1155/2012/656340)
128. Ryder M, Callahan M, Postow MA, Wolchok J & Fagin JA 2014 Endocrine-related adverse events following ipilimumab in patients with advanced melanoma: a comprehensive retrospective review from a single institution. Endocrine-Related Cancer 21 371–381. (doi:10.1530/ERC-13-0499)
129. Sangro B, Gomez-Martin C, de la Mata M, Iñarrairaegui M, Garralda E, Barrera P, Riezu-Boj JI, Larrea E, Alfaro C, Sarobe P, et al. 2013 A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. Journal of Hepatology 59 81–88. (doi:10.1016/j.jhep.2013.02.022)
130. Sarnaik AA, Yu B, Yu D, Morelli D, Hall M, Bogle D, Yan L, Targan S, Solomon J, Nichol G, et al. 2011 Extended dose ipilimumab with a peptide vaccine: immune correlates associated with clinical benefit in patients with resected high-risk stage IIIc/IV melanoma. Clinical Cancer Research 17 896–906. (doi:10.1158/1078-0432.CCR-10-2463)
131. Schubert D, Bode C, Kenefeck R, Hou TZ, Wing JB, Kennedy A, Bulashevska A, Petersen BS, Schäffer AA, Grüning BA, et al. 2014 Autosomal dominant immune dysregulation syndrome in humans with CTLA4 mutations. Nature Medicine 20 1410–1416. (doi:10.1038/ nm.3746)
132. Segal NH, Antonia SJ, Brahmer JR, Maio M, Blake-Haskins A, Li X, Vasselli J, Ibrahim RA, Lutzky J & Khleif S 2014 Preliminary data from a multi-arm expansion study of MEDI4736, an anti-PD-L1 antibody. Journal of Clinical Oncology 32 (15 Suppl) 3002. (doi:10.1200/jco.2014.32.15_suppl.3002)
133. Segal NH, Ou SHI, Balmanoukian AS, Massarelli E, Brahmer JR, Weiss J, Schoffski P, Antonia SJ, Massard C, Zandberg DP, et al. 2016 Updated safety and efficacy of durvalumab (MEDI4736), an anti-PD-L 1 antibody, in patients from a squamous cell carcinoma of the head and neck (SCCHN) expansion cohort. Annals of Oncology 27 949O. (doi:10.1093/annonc/mdw376)
134. Seiwert TY, Burtness B, Mehra R, Weiss J, Berger R, Eder JP, Heath K, McClanahan T, Lunceford J, Gause C, et al. 2016 Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial. Lancet Oncology 17 956–965. (doi:10.1016/S1470-2045(16)30066-3)
135. Shahabi V, Postow MA, Tuck D & Wolchok JD 2015 Immune-priming of the tumor microenvironment by radiotherapy: rationale for combination with immunotherapy to improve anticancer efficacy. American Journal of Clinical Oncology 38 90–97. (doi:10.1097/ COC.0b013e3182868ec8)
136. Shitara K, Yamada Y, Yoh K, Naito Y, Iwasa S, Yamamoto N, Heydebreck Av, Achiwa H & Doi T 2015 Phase I, open-label, multi-ascending dose trial of avelumab (MSB0010718C), an anti-PD-L1 monoclonal antibody, in Japanese patients with advanced solid tumors. Journal of Clinical Oncology 33 (15 Suppl) 3023. (doi:10.1200/ jco.2015.33.15_suppl.3023)
137. Spigel DR, Gettinger SN, Horn L, Herbst RS, Gandhi L, Gordon MS, Cruz C, Conkling P, Cassier PA, Antonia SJ, et al. 2013 Clinical activity, safety, and biomarkers of MPDL3280A, an engineered PD-L1 antibody in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC). Journal of Clinical Oncology 31 (15 Suppl) 8008. (doi:10.1200/jco.2013.31.15_suppl.8008)
138. Slovin SF, Higano CS, Hamid O, Tejwani S, Harzstark A, Alumkal JJ, Scher HI, Chin K, Gagnier P, McHenry MB, et al. 2013 Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study. Annals of Oncology 24 1813–1821. (doi:10.1093/ annonc/mdt107)
139. Spira AI, Park K, Mazières J, Vansteenkiste JF, Rittmeyer A, Ballinger M, Waterkamp D, Kowanetz M, Mokatrin A & Fehrenbacher L 2015 Efficacy, safety and predictive biomarker results from a randomized phase II study comparing MPDL3280A vs docetaxel in 2L/3L NSCLC (POPLAR). Journal of Clinical Oncology 33 (15 Suppl) 8010. (doi:10.1200/jco.2015.33.15_suppl.8010)
140. Stamell EF, Wolchok JD, Gnjatic S, Lee NY & Brownell I 2013 The abscopal effect associated with a systemic anti-melanoma immune response. International Journal of Radiation Oncology, Biology, Physics 85 293–295. (doi:10.1016/j.ijrobp.2012.03.017)
141. Streilein JW 2003 Ocular immune privilege: therapeutic opportunities from an experiment of nature. Nature Reviews Immunology 3 879–889. (doi:10.1038/nri1224)
142. Tarhini AA, Cherian J, Moschos SJ, Tawbi HA, Shuai Y, Gooding WE, Sander C & Kirkwood JM 2012 Safety and efficacy of combination immunotherapy with interferon alfa-2b and tremelimumab in patients with stage IV melanoma. Journal of Clinical Oncology 30 322–328. (doi:10.1200/JCO.2011.37.5394)
143. Teulings H-E, Limpens J, Jansen SN, Zwinderman AH, Reitsma JB, Spuls PI & Luiten RM 2015 Vitiligo-like depigmentation in patients with stage III-IV melanoma receiving immunotherapy and its association with survival: a systematic review and meta-analysis. Journal of Clinical Oncology 33 773–781. (doi:10.1200/ JCO.2014.57.4756)
144. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, Powderly JD, Carvajal RD, Sosman JA, Atkins MB, et al. 2012 Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. New England Journal of Medicine 366 2443–2454. (doi:10.1056/NEJMoa1200690)
145. Topalian SL, Sznol M, McDermott DF, Kluger HM, Carvajal RD, Sharfman WH, Brahmer JR, Lawrence DP, Atkins MB, Powderly JD, et al. 2014 Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. Journal of Clinical Oncology 32 1020–1030. (doi:10.1200/JCO.2013.53.0105)
146. Ueda H, Howson JMM, Esposito L, Heward J, Snook, Chamberlain G, Rainbow DB, Hunter KMD, Smith AN, Di Genova G, et al. 2003 Association of the T-cell regulatory gene CTLA4 with susceptibility to autoimmune disease. Nature 423 506–511. (doi:10.1038/ nature01621)
147. van der Hiel B, Blank CU, Haanen JB & Stokkel MP 2013 Detection of early onset of hypophysitis by (18)F-FDG PET-CT in a patient with advanced stage melanoma treated with ipilimumab. Clinical Nuclear Medicine 38 e182–e184. (doi:10.1097/RLU.0b013e3182639765)
148. Varga A, Piha-Paul SA, Ott PA, Mehnert JM, Berton-Rigaud D, Johnson EA, Cheng JD, Yuan S, Rubin EH & Matei DE 2015 Antitumor activity and safety of pembrolizumab in patients (pts) with PD-L1 positive advanced ovarian cancer: Interim results from a phase Ib study. Journal of Clinical Oncology 33 (15 Suppl) 5510. (doi:10.1200/jco.2015.33.15_suppl.5510)
149. Vidarsson G, Dekkers G & Rispens T 2014 IgG subclasses and allotypes: from structure to effector functions. Frontiers in Immunology 5 520. (doi:10.3389/fimmu.2014.00520)
150. Weber J 2009 Ipilimumab: controversies in its development, utility and autoimmune adverse events. Cancer Immunology, Immunotherapy 58 823–830. (doi:10.1007/s00262-008-0653-8)
151. Weber J, O’Day S, Urba W, Powderly J, Nichol G, Yellin M, Snively J & Hersh E 2008 Phase I/II study of ipilimumab for patients with metastaticmelanoma. Journal of Clinical Oncology 26 5950–5956. (doi:10.1200/JCO.2008.16.1927)
152. Weber J, Thompson JA, Hamid O, Minor D, Amin A, Ron I, Ridolfi R, Assi H, Maraveyas A, Berman D, et al. 2009 A randomized, double-blind, placebo-controlled, phase II study comparing the tolerability and efficacy of ipilimumabadministered with or without prophylactic budesonide in patients with unresectable stage III or IV melanoma. Clinical Cancer Research 15 5591–5598. (doi:10.1158/1078-0432.CCR-09-1024)
153. Weber JS, Kudchadkar RR, Yu B, Gallenstein D, Horak CE, Inzunza HD, Zhao X, Martinez AJ, Wang W, Gibney G, et al. 2013 Safety, efficacy, and biomarkers of nivolumab with vaccine in ipilimumab-refractory or -naive melanoma. Journal of Clinical Oncology 31 4311–4318. (doi:10.1200/JCO.2013.51.4802)
154. Weber JS, D’Angelo SP, Minor D, Hodi FS, Gutzmer R, Neyns B, Hoeller C, Khushalani NI, Miller WH, Lao CD, et al. 2015a Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncology 16 375–384. (doi:10.1016/S1470-2045(15)70076-8)
155. Weber JS, Gibney GT, Yu B, Cheng PY, Martinez AJ, Kroeger J, Freed J, Richards A, Zhao X & Schell MJ 2015b Survival, biomarker, and toxicity analysis of nivolumab (NIVO) in patients that progressed on ipilimumab (IPI). Journal of Clinical Oncology 33 (15 Suppl) 9055. (doi:10.1200/jco.2015.33.15_suppl.9055)
156. Weber J, Mandala M, Del Vecchio M, Gogas HJ, Arance AM, Cowey CL, Dalle S, Schenker M, Chiarion-Sileni V, Marquez-Rodas I, et al. 2017 Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma. New England Journal of Medicine [in press]. (doi:10.1056/ NEJMoa1709030)
157. Win MA, Thein KZ, Qdaisat A & Yeung SJ 2017 Acute symptomatic hypocalcemia from immune checkpoint therapy-induced hypoparathyroidism. American Journal of Emergency Medicine 35 1039. e5–1039.e7. (doi:10.1016/j.ajem.2017.02.048)
158. Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, Waterfield W, Schadendorf D, Smylie M, Guthrie T, et al. 2010 Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncology 11 155–164. (doi:10.1016/S1470-2045(09)70334-1)
159. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, Segal NH, Ariyan CE, Gordon RA, Reed K, et al. 2013 Nivolumab plus ipilimumab in advanced melanoma. New England Journal of Medicine 369 122–133. (doi:10.1056/NEJMoa1302369)
160. Yamada Y, Nishina T, Iwasa S, Shitara K, Muro K, Esaki T, Hironaka S, Yamaguchi K, Machida N, Satoh T, et al. 2015 A phase I dose expansion trial of avelumab (MSB0010718C), an anti-PD-L1 antibody, in Japanese patients with advanced gastric cancer. Journal of Clinical Oncology 33 (15 Suppl) 4047. (doi:10.1200/jco.2015.33.15_ suppl.4047)
161. Yang JC, Hughes M, Kammula U, Royal R, Sherry RM, Topalian SL, Suri KB, Levy C, Allen T, Mavroukakis S, et al. 2007 Ipilimumab (anti-CTLA4 antibody) causes regression of metastatic renal cell cancer associated with enteritis and hypophysitis. Journal of Immunotherapy 30 825–830. (doi:10.1097/CJI.0b013e318156e47e)
162. Yeh OL & Francis CE 2015 Ipilimumab-associated bilateral optic neuropathy. Journal of Neuro-Ophthalmology 35 144–147. (doi:10.1097/WNO.0000000000000217)
163. Yu C, Chopra IJ & Ha E 2015 A novel melanoma therapy stirs up a storm: ipilimumab-induced thyrotoxicosis. Endocrinology, Diabetes and Metabolism Case Reports 2015 article ID 14-0092. (doi:10.1530/ EDM-14-0092)